Member Info for EmeraldCarrots

Erm 7p a share. It's only 1.1p to buy NOW!!!!!!!!!!!!!!

AI Overview

Yes, CelLBxHealth Plc (CLBX) (also known as Angle Plc) currently holds a "Strong Buy" consensus rating from analysts, with an average 12-month price target suggesting significant upside from its current levels, reflecting positive analyst sentiment for its cancer diagnostics technology, such as the Parsortix system, according to sources like MSN, Investing.com, and Yahoo Finance https://www.msn.com/en-us/money/stockdetails/clbx-gb-stock/fi-ao5r27?ocid=U146DDHP, https://uk.investing.com/equities/angle-plc-consensus-estimates,.

Key Analyst Insights:

Consensus: "Strong Buy," based on recommendations from multiple analysts.

Price Target: Around 7.00 (GBp), indicating a large potential percentage gain.

Upside: Analysts project substantial upside, potentially over 650%.

Underlying Tech: The company focuses on capturing rare cells from blood for cancer and fetal health.

What "Strong Buy" Means:

A strong buy signifies that analysts expect significant positive financial performance and favorable market conditions for the stock.

Where to Find More:

You can view detailed analyst ratings and price targets on financial sites like Investing.com, MSN Money, and Yahoo Finance.

Or is there news from Immatics regarding the phase 3 cancer drug trial parsortix is used in? Or indeed the other 2 cancer drug trials???

?

+ 27.03%

Your previous post:-

"No shares available to buy in decent quantities. Extremely hard to buy, This SP is going Higher.".

I rest my case!

Andrew4444

"I can buy a million with HL"

====================

Tempted?

Up 24.32%.

Says it all.

Up 24.32%.

fb2020.

Ramping shares by implying you can't get any is incorrect and rather silly IMHO.

Try and buy a large amount then carrot ! I have been trying for 45 mins to fill one order .

also get level 2 with order book and you can see the buy order !

Cretin

==============

Thanks! LOL! Maybe you need another broker? Does your one operate from a market stall in the high street?

Makes sense to me.

Fb2020.

"No shares available to buy in decent quantities."

===================

What a load of rubbish!

.

Machine supply Company has not tried to get an exclusive USA deal with Genedrive. Exclusive license to sell it maybe!

https://www.lse.co.uk/rns/GDR/breakthrough-device-designation-from-the-us-fda-2zclfstav7guqaq.html

.

This is what the Company should be targeting. Mr Nugent and Mr English would make tens of millions on FDA approval for the MT-RNR1 IMHO.

https://www.lse.co.uk/rns/GDR/breakthrough-device-designation-from-the-us-fda-2zclfstav7guqaq.html

It seems.

???

Market cap based on todays mid price:-

"No. of Securities in issue: 1,139,402,658 ordinary shares of 0.05 pence each." From their web site.

1,139,402,658 x .0105 = £11,963,727, So £12m ish.

Https://immatics.com/our-pipeline/

"what is MRNA-4203?"

mRNA-4203 is an investigational messenger RNA (mRNA) therapy developed by Moderna, designed to be used with Immatics' T-cell therapy (IMA203) to treat cancers like melanoma and synovial sarcoma, acting as a vaccine to boost the immune system's ability to target cancer cells and enhance the T-cells' effectiveness. It encodes the PRAME tumor antigen and is currently in Phase 1 clinical trials, delivered via lipid nanoparticles (LNPs) to improve the killing power of the modified T-cells.

How it Works:

Targeting Cancer: Both IMA203 (TCR T-cell therapy) and mRNA-4203 target PRAME, a protein found on certain cancer cells, including melanoma and synovial sarcoma.

Immune Activation: mRNA-4203 delivers instructions (mRNA) for making the PRAME antigen to the body's immune cells.

Boosting T-Cells: This process activates the immune system and enhances the function of the T-cells (IMA203) to better recognize and destroy cancer cells.

Clinical Trial:

It's part of a Phase 1 trial (NCT06946225) combining it with IMA203.

The goal is to assess safety, tolerability, and anti-tumor activity in patients with advanced melanoma or synovial sarcoma.

In essence, mRNA-4203 acts as a "booster shot" for the T-cell therapy, making it a more potent weapon against cancer.